
Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.

A single-arm, prospective trial found that botulinum toxin injections did not have a significant effect on symptoms one month after treatment.

Researchers explored the relationship between psoriasis severity and its link to coronary microvascular dysfunction in the largest such study to date.

When combining adalimumab with surgery, patient outcomes, including quality of life, were improved.

Zoe Diana Draelos, MD, developed the study to examine the efficacy and tolerability of a once-daily 3% salicylic acid treatment gel containing turmeric, a low concentration of salicylic acid, and shea butter exfoliating moisturizer in the management of psoriasis flare-ups, either as a monotherapy or as a supplement to other psoriasis treatment regimens.

In this week’s Pointers With Portela, the 208SkinDoc reviews fungal acne and his recommended treatment strategy.

A patient’s journey toward weight loss for overall better health involves multifaceted considerations that extend beyond the numbers on a scale when it comes to sagging or excess skin.


Jeffrey Yager, MD, discusses the new SY Aesthetics campus that will integrate traditional and Chinese healing.

Keep up with the latest headlines in dermatology from the past week, including efforts to raise awareness about the importance of skin checks and sun protection, CeraVe's role in expanding a dermatology residency training program, and more.

ICYMI, this week we had articles about periorbital rejuvenation, treating all skin tones, improving basal cell carcinoma management, and more.

Eligible candidates should apply by October 15, 2023, and one candidate will match in March 2024.

Efficacy of 1% colloidal oatmeal cream was similar to prescription barrier cream in treating mild to moderate atopic dermatitis.

A systematic review found that generally, combination therapy has evidence supportive of its efficacy in hidradenitis suppurativa.

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

Today is National Native American Day. Dermatology Times is reviewing the unique dermatologic concerns and disparities faced by members of the Native and Indigenous communities.

Research has shown that biosimilars are highly similar to their originator product in terms of safety and efficacy.

Full clearance of recalcitrant warts was achieved in 68.6% of patients.

Share your insights ahead of October's National Eczema Awareness Month by emailing our team at DTEditor@mmhgroup.com.

Yale School of Medicine researchers found tetracycline-class antibiotics were the most prescribed acne treatment for adult female patients between 2002 and 2016.

Public health/public policy researcher and New York Times best-selling author Marty Makary, MD, MPH, FACS, discusses the role of physician-led legislative advocacy in health care and dermatology.

While some resistance was noted against azithromycin, clindamycin, and erythromycin, they were not statistically significant.

Among the many sessions to be held at the 2023 Science of Skincare Summit in Austin, Texas, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Changes to skin and nerve endings as a result of HS may contribute to peripheral neuropathy.

Multiple microinjections significantly improved signs of aging up to 12 weeks after initial injection.

FDA action is no longer expected in Q3 of 2023.

Prior research has demonstrated an association between religious headwear and traction alopecia.

This week’s collection of the latest dermatologic studies covers dermatologic care for patients with disorders of sex development, stem cell transplantation for vitiligo, switching biologic therapies for psoriasis, and combination therapy for hidradenitis suppurativa.